Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 monoclonal antibody plus multimodality radiotherapy for advanced cholangiocarcinoma after first-line progression
ChiCTR2100053331Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PD-1 Monoclonal Antibody in cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival. Started Nov 2021; status: recruiting.
02
Drugs
PD-1 Monoclonal Antibody
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2100053331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053331.